- Home
- BBIO vs LNTH Comparison
BBIO vs LNTH Comparison
Compare BBIO & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | LNTH |
|---|---|---|
| Founded | 2015 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 4.2B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BBIO | LNTH |
|---|---|---|
| Price | $74.97 | $66.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 6 |
| Target Price | $75.75 | ★ $77.33 |
| AVG Volume (30 Days) | ★ 2.0M | 1.0M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.39 |
| Revenue | $353,780,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $128.44 | $0.01 |
| Revenue Next Year | $76.14 | $1.24 |
| P/E Ratio | ★ N/A | $27.84 |
| Revenue Growth | ★ 62.46 | 1.95 |
| 52 Week Low | $25.34 | $47.25 |
| 52 Week High | $75.24 | $111.29 |
Technical Indicators
Market Signals| Indicator | BBIO | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 68.19 | 72.55 |
| Support Level | $70.35 | $60.15 |
| Resistance Level | $75.10 | $64.40 |
| Average True Range (ATR) | 2.33 | 2.09 |
| MACD | -0.13 | 0.66 |
| Stochastic Oscillator | 98.77 | 94.44 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.